Magee L A, Yong P J, Espinosa V, Côté A M, Chen I, von Dadelszen P
Departments of Medicine, University of British Columbia, Vancouver, BC, V6H 3N1, Canada.
Hypertens Pregnancy. 2009;28(3):312-47. doi: 10.1080/10641950802601252.
To compare outcomes associated with expectant vs. interventionist care of severe preeclampsia in observational studies.
Medline (01/1980-07/2007), bibliographies of retrieved papers, personal files, Cochrane Database of Systematic Reviews.
Expectant or interventionist care of preeclampsia at <34 wk. TABULATION, INTEGRATION, RESULTS: Data abstraction independently by two reviewers. Median [IQR] of clinical maternal/perinatal outcomes presented.
72 publications, primarily from tertiary care centres in Dutch and developed world sites. Expectant care of severe preeclampsia <34 wk (39 cohorts, 4,650 women), for which 40% of women are eligible, is associated with pregnancy prolongation of 7-14 d, and few serious maternal complications (median <5%), similar to interventionist care (2 studies, 42 women). Complication rates are higher with HELLP <34wk (12 cohorts, 438 women) and severe preeclampsia <28wk (6 cohorts, 305 women), similar to interventionist care (6 cohorts, 467 women and 2 cohorts, 70 women, respectively). Expectant care of HELLP <34 wk (12 cohorts, 438 women) is associated with fewer days gained (median 5), but more serious maternal morbidity (e.g., eclampsia, median 15%). More than half of women have at least temporary improvement of HELLP. In the developed world, expectant (vs. interventionist) care of severe preeclampsia or HELLP <34 wk is associated with reduced neonatal death and complications. Stillbirth is higher in Dutch and developing world sites where viability thresholds are higher. For preeclampsia <24wk (4 cohorts), perinatal mortality is >80%. No predictors of adverse maternal/perinatal outcomes were identified (13 studies).
Future research should establish the best maternal/fetal monito regimen and indications for delivery with expectant care. A definitive RCT is needed.
在观察性研究中比较重度子痫前期期待治疗与干预性治疗的结局。
医学文献数据库(1980年1月至2007年7月)、检索论文的参考文献、个人档案、Cochrane系统评价数据库。
孕周<34周的子痫前期的期待治疗或干预性治疗。制表、整合、结果:由两名审阅者独立提取数据。呈现临床孕产妇/围产儿结局的中位数[四分位间距]。
72篇出版物,主要来自荷兰和发达国家的三级医疗中心。孕周<34周的重度子痫前期的期待治疗(39个队列,4650名女性),其中40%的女性符合条件,与孕周延长7 - 14天相关,且严重孕产妇并发症较少(中位数<5%),与干预性治疗相似(2项研究,42名女性)。孕周<34周的HELLP综合征(12个队列,438名女性)和孕周<28周的重度子痫前期(6个队列,305名女性)的并发症发生率较高,与干预性治疗相似(分别为6个队列,467名女性和2个队列,70名女性)。孕周<34周的HELLP综合征的期待治疗(12个队列,438名女性)与延长天数较少(中位数5天)相关,但孕产妇严重发病率较高(如子痫,中位数15%)。超过一半的女性HELLP综合征至少有暂时改善。在发达国家,孕周<34周的重度子痫前期或HELLP综合征的期待治疗(与干预性治疗相比)与新生儿死亡和并发症减少相关。在荷兰和发展中国家,由于存活阈值较高,死产率较高。对于孕周<24周的子痫前期(4个队列),围产儿死亡率>80%。未发现孕产妇/围产儿不良结局的预测因素(13项研究)。
未来研究应确定期待治疗中最佳的孕产妇/胎儿监测方案和分娩指征。需要进行一项确定性随机对照试验。